Details for New Drug Application (NDA): 018017
✉ Email this page to a colleague
The generic ingredient in BLOCADREN is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.
Summary for 018017
| Tradename: | BLOCADREN |
| Applicant: | Merck |
| Ingredient: | timolol maleate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 018017
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | BLOCADREN | timolol maleate | TABLET;ORAL | 018017-001 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Get Started Free |
| Merck | BLOCADREN | timolol maleate | TABLET;ORAL | 018017-004 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Get Started Free |
| Merck | BLOCADREN | timolol maleate | TABLET;ORAL | 018017-002 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
